Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral GPC3-CART in Advanced HCC
NCT03130712Phase 2Unknown
- Sponsor
- Shanghai Genechem
- Start
- Apr 2017
- Primary completion
- Mar 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GPC3-CART cells in hepatocellular carcinoma (HCC), sponsored by Shanghai Genechem. Primary endpoint: Number of participants with Adverse Events at 6 weeks. Status: unknown.
02
Drugs
GPC3-CART cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03130712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03130712.